| Author/Editor | Gregorič, Brigita; Zadnik, Vesna; Jezeršek-Novaković, Barbara | |
| Title | The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice | |
| Translated title | Difuzni velikocelični limfom B - današnja vsakodnevna klinična praksa | |
| Type | članek | |
| Source | Radiol Oncol | |
| Vol. and No. | Letnik 46, št. 2 | |
| Publication year | 2012 | |
| Volume | str. 153-9 | |
| Language | eng | |
| Abstract | Background. Due to superior results observed with the addition of rituximab into treatment of patients with the diffuse large B-cell lymphoma (DLBCL),the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen and its variants became the standard initial treatment of these patients. However, the treatment recommendations are based on resultsof clinical studies while the conditions of routine treatment are far different from the ones in clinical studies. The aim of this retrospective study was therefore to compare the treatment results of routinelz treated patients with the DLBCL to results reported by some larger studies. Patients and methods. Two hundred and ninety five patients with the DLBCL were treated between 2004 and 2008 according to the then protocol with R-CHOP or R-CHOP-like regimens at the Institute of Oncology Ljubljana. Treatment response was evaluated according to Cheson's criteria and the disease-free andoverall survival by means of Kaplan Meier survival curves. Results. Response to treatment in our evaluation diverged from the reported one predominately in the low risk group (international prognostic index [IPI] categorisation) and in the very good prognosis group (revised international prognostic index (R-IPI) categorisation). The determined complete response (CR) rates in other IPI and R-IPI groups were generally within expectations. Also in the disease-free survival the largest discrepancy occurred in the low-risk patient group (3 year disease-free survival rate of 75%) and in the very good prognosis group (4 year disease-free survival rate of 59%). In all other IPI risk groups, the disease-free survival at 3 zears (low intermediate risk 76%, high intermediate risk group 57%, and high risk group 53%) agreed verz well with the quoted ones. (Abstract truncated at 2000 characters) | |
| Descriptors | LYMPHOMA, B-CELL LYMPHOMA, DIFFUSE TREATMENT OUTCOME SURVIVAL ANALYSIS DISEASE-FREE SURVIVAL |